Xenon Pharmaceuticals reported compelling Phase III results for azetukalner, a Kv7 potassium-channel opener, showing a large placebo‑adjusted reduction in focal onset seizure frequency. The company said the high‑dose cohort achieved a statistically robust decrease, prompting plans for an FDA submission in the third quarter. The readout reverses earlier skepticism about Kv7 programs and lifts investor interest. The results come from the X‑TOLE2 pivotal study and were highlighted in company releases and clinical reports; Xenon cited strong tolerability at the commercially attractive 15 mg dose. Analysts noted the magnitude of the effect compares favorably with prior late‑stage epilepsy drugs, and Xenon expects to dossier the drug after regulatory discussions. Kv7 is an ion‑channel target implicated in neuronal excitability; reopening that target could spur new entrants and partnerships.